1. Home
  2. STVN vs DNLI Comparison

STVN vs DNLI Comparison

Compare STVN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$19.92

Market Cap

3.7B

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$23.67

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STVN
DNLI
Founded
1949
2013
Country
Italy
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.7B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
STVN
DNLI
Price
$19.92
$23.67
Analyst Decision
Buy
Strong Buy
Analyst Count
3
14
Target Price
$25.67
$34.33
AVG Volume (30 Days)
269.4K
1.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
0.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.67
N/A
Revenue Next Year
$9.99
$408.85
P/E Ratio
$27.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.89
$12.58
52 Week High
$28.00
$27.30

Technical Indicators

Market Signals
Indicator
STVN
DNLI
Relative Strength Index (RSI) 59.95 49.75
Support Level $18.74 $18.27
Resistance Level $20.27 $27.30
Average True Range (ATR) 0.80 1.34
MACD -0.01 -0.32
Stochastic Oscillator 74.60 31.57

Price Performance

Historical Comparison
STVN
DNLI

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: